Furthermore, the studies from Ling et al. found that targeting DDX5 by the small molecule FL118 exhibits high efficacy to inhibit PDAC patient-derived xenograft (PDX) tumor growth and induces tumor regression/elimination in immunocompromised mice (see below for more information) [46]. This evidence concerns the gene DDX5 and neoplasm.